Foamix To Present At The 34th Annual Cowen and Company Health Care Conference -- Successful Phase 2 For First Ever Topical Minocycline For Acne And Impetigo
2/27/2014 9:15:05 AM
REHOVOT, Israel, Feb. 27, 2014 (GLOBE NEWSWIRE) -- Foamix, a clinical-stage, privately held specialty pharmaceutical company, focused on the development of proprietary topical foams for dermatology for itself and major pharmaceutical licensees, today announced that Dr. Dov Tamarkin, Chief Executive Officer, will speak at the Cowen & Company 34th Annual Health Care Conference, being held at the Boston Marriott Copley Place in Boston, Massachusetts, March 3-5, 2014. Dr. Tamarkin will provide an overview of the Company's business and commercial strategy. He will reveal successful results from Phase 2 Acne and Impetigo (including MRSA impetigo) clinical trials; and how the Company is transforming from a technology-based, licensing company into a commercial specialty pharmaceutical company.
Help employers find you! Check out all the jobs and post your resume.
comments powered by